Filtered By:
Source: Current Pharmaceutical Design

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 176 results found since Jan 2013.

Brain Drug Delivery Systems for the Stroke Intervention and Recovery.
CONCLUSION: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery. PMID: 27784243 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 24, 2016 Category: Drugs & Pharmacology Authors: Luo T, Wang J, Hao S, Guo T, Ren P, Cheng Z, Gao F, Gong Y, Wang B Tags: Curr Pharm Des Source Type: research

Mutations of mitochondrial DNA in chronic non-inflammatory diseases: target candidates for treatment.
Abstract The present article considers chronic diseases of non-inflammatory genesis, the reasons of which may be mitochondrial dysfunctions. Among them are: coronary heart disease (CHD), hypertension, cardiomyopathy, cerebrovascular accidents and type 2 diabetes mellitus (T2D). Very often, in the long course of the disease, complications may occur, leading to myocardial infarction or ischemic stroke and as a result, death. The main cause of mitochondrial dysfunction are point mitochondrial genome mutations. During the analysis of the literature, data showing the association of the mitochondrial genome mutations wi...
Source: Current Pharmaceutical Design - October 17, 2016 Category: Drugs & Pharmacology Authors: Galitsyna EV, Sazonova MA, Shkurat TP, Demakova NA, Melnichenko AA, Sinyov VV, Ryzhkova AI, Mitrofanov KY, Zhelankin AV, Sobenin IA, Orekhov AN Tags: Curr Pharm Des Source Type: research

Precision medicine and a patient-orientated approach: is this the future for tracking Cardiovascular Disorders?
Abstract The latest statistics from the 2016 heart disease and stroke statistics update shows that cardiovascular disease is the leading global cause of death, currently accounting for more than 17.3 million deaths per year. Type II diabetes is also on the rise with out-of-control numbers. To address these pandemics, we need to treat patients using an individualized patient care approach, but simultaneously gather data to support the precision medicine initiative. Last year the NIH announced the precision medicine initiative to generate novel knowledge regarding diseases, with a near-term focus on cancers, followe...
Source: Current Pharmaceutical Design - October 5, 2016 Category: Drugs & Pharmacology Authors: Pretorius E Tags: Curr Pharm Des Source Type: research

Antiplatelet treatment in stroke: new insights.
CONCLUSIONS: Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke or transient ischemic attack. Moreover, clinicians should carefully assess the pros and cons in each case and individualize the need for prolonged dual antiplatelet therapy. PMID: 27291399 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 8, 2016 Category: Drugs & Pharmacology Authors: Milionis H, Liontos A, Vemmos K, Spengos K Tags: Curr Pharm Des Source Type: research

P2Y12 receptor antagonists: which one to choose? A systematic review and meta-analysis.
Conclusion: Newer P2Y12 receptor antagonists are associated with better cardiovascular outcomes in patients with ACS and/or undergoing PCI. Prasugrel use resulted in higher major bleeding rates and no overall mortality benefit compared with clopidogrel. PMID: 27290917 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 7, 2016 Category: Drugs & Pharmacology Authors: Briasoulis A, Telila T, Palla M, Siasos G, Tousoulis D Tags: Curr Pharm Des Source Type: research

The interaction between gender and diabetes mellitus in the coronary heart disease risk.
CONCLUSION: The connection between diabetes mellitus and cardiovascular disease is variable according to gender and further studies are needed to elucidate the lenient differentiations in gender specific hormones, risk factor profile, and therapeutic implications between genders. PMID: 27280390 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 5, 2016 Category: Drugs & Pharmacology Authors: Oikonomou E, Tsigkou V, Lazaros G, Papamikroulis GA, Papaioannou S, Siasos G, Tousoulis D Tags: Curr Pharm Des Source Type: research

Dual or single antiplatelet therapy after transcatheter aortic valve implantation? A systematic review and meta-analysis.
CONCLUSION: DAPT compared to SAPT in patients after TAVI increases incidence of hemorrhagic events with no benefits in terms of thrombotic events and cardiovascular mortality. However, these data must be interpreted cautiously and the choice of DAPT over SAPT must be based on an individual patient characteristic according to medical practice criteria. PMID: 27262328 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 31, 2016 Category: Drugs & Pharmacology Authors: Raut JS, Karuppayil SM, Gazouli M, Vavuranakis M, Siasos G, Zografos T, Oikonomou E, Vrachatis D, Kalogeras K, Papaioannou T, Kolokathis MA, Moldovan C, Tousoulis D Tags: Curr Pharm Des Source Type: research

Genetics in anti-platelet treatment.
Abstract Anti-platelet drugs are necessary in treating patients with coronary artery disease, ischemic stroke and peripheral arterial disease. However, despite the use of adequate anti-platelet therapy, some patients will experience a recurrent atherothrombotic vascular event. These patients are characterized as low- or non-responders to therapy. Individual responsiveness to anti-platelet therapy as the use of clopidogrel and/or aspirin varies widely among patients. Such an individual variability is mainly determined by environmental and genetic factors. In this review, we focused on the underlying genetic mechani...
Source: Current Pharmaceutical Design - May 30, 2016 Category: Drugs & Pharmacology Authors: Raut JS, Karuppayil SM, Gazouli M Tags: Curr Pharm Des Source Type: research

Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid syndrome: Towards Pathophysiology-Based Treatment.
Abstract Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by a persistently high titer of antiphospholipid antibodies (aPLs). In addition to pregnancy morbidity, arterial and/or venous thrombosis is another clinical feature of APS. Regardless of the type of APS, the thrombi formed by the induction of aPLs can lead to deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke and gangrene. Although the concept of APS was introduced approximately 32 years ago, its thrombogenic pathophysiology is still unclear. Therefore, patients are treated with anticoagulant and/or antipl...
Source: Current Pharmaceutical Design - May 26, 2016 Category: Drugs & Pharmacology Authors: Asiful Islam M, Alam F, Sasongko TH, Gan SH Tags: Curr Pharm Des Source Type: research

Statins in stroke prevention: present and future.
CONCLUSION: Traditionally, there has been no clear data demonstrating that adding other lipid-modifying drugs to statins results in a further decrease in stroke or other cardiovascular event, but now things have changed and future directions include combinations with ezetimibe and new treatments such as PCSK9 inhibitors. Only time will tell the real roll of these new promising non-statin lipid-modifying therapies on stroke prevention. PMID: 27160755 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 9, 2016 Category: Drugs & Pharmacology Authors: Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA Tags: Curr Pharm Des Source Type: research

Gender and Cardiovascular Mortality in Northern and Ssouthern European Populations.
CONCLUSION: No doubt might still exist that all efforts were undertaken for both men and women, for health and prolongation of life to effectively treat common risk factors such as cigarette consumption, high blood pressure, cholesterol levels and physical inactivity by also paying attention to optimal diet. PMID: 27138925 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 1, 2016 Category: Drugs & Pharmacology Authors: Puddu PE, Schiariti M, Torromeo C Tags: Curr Pharm Des Source Type: research

Neurotrophic and Neuroprotective effects of muscle contraction.
CONCLUSION: Physical activity could represent an additional approach to fight against such diseases. PMID: 27121507 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - April 27, 2016 Category: Drugs & Pharmacology Authors: Arnao V, Di Raimondo D, Tuttolomondo A, Pinto A Tags: Curr Pharm Des Source Type: research

Stroke and Neuroinflamation: Role of Sexual Hormones.
Abstract Inflammatory response in the nervous system, called neuroinflammation, is a common process of several neurodegenerative diseases and brain disorders. To understand the underlying mechanism of this brain response to damage would be interesting to identify new common therapy targets to neurodegenerative processes. Ischemic stroke has an important socioeconomic impact being the second cause of mortality and the first cause of long-term disability in the world. Until now, there is not any pharmacological treatment to reduce the brain damage induced. In this review, we will expose recent evidences about neuroi...
Source: Current Pharmaceutical Design - March 15, 2016 Category: Drugs & Pharmacology Authors: Perez-Alvarez MJ, Wandosell F Tags: Curr Pharm Des Source Type: research

Atypical chest pain in ACS: a trap especially for women.
Abstract Not all acute coronary syndromes (ACS) exhibit the classic symptoms of chest pain. The diagnosis of ACS in patients without typical chest pain is often challenging. These patients are at increased risk for delayed or incorrect diagnosis, less aggressive treatment and high in-hospital mortality. The association between diabetes mellitus and absence of chest pain in ischemic heart disease is established. As well, it is known that women, more frequently than men, have atypical presentation. However, there is a lack of standardization in characterizing the population of patients with ACS and atypical presenta...
Source: Current Pharmaceutical Design - March 8, 2016 Category: Drugs & Pharmacology Authors: Ricci B, Cenko E, Varotti E, Puddu PE, Manfrini O Tags: Curr Pharm Des Source Type: research

Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness.
Conclusions The present study demonstrated no significant differences in regards to mortality or stroke between the two therapeutic procedures. However, the cost-effectiveness and long-term efficacy of TAVI may require further investigation. Technological improvement and increased experience may broaden the clinical indication for TAVI for low-intermediate risk patients in the future. PMID: 26891807 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 19, 2016 Category: Drugs & Pharmacology Authors: Cao C, Liou KP, Pathan FK, Virk S, McMonnies R, Wolfenden H, Indraratna P Tags: Curr Pharm Des Source Type: research